Alejandro Alva, MD
Psychiatry · Costa Mesa, CANPI 1801816764
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 51 manufacturers reported payments, led by Alkermes, Inc. at 28.9% of the total. 2025 is the largest year on record at $77,471, 2.6 times the $30,352 reported in 2019. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,979 payments — averaging $136.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$78K
- Teva Pharmaceuticals USA, Inc.$66K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$40K
- H. Lundbeck A S$26K
- Neurocrine Biosciences, Inc.$11K
- MDD US Operations, LLC$10K
- plus $39K from 45 others
Across 560 payments — averaging $2121.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$816K
- Regeneron$130K
- Janssen Research & Development, LLC$113K
- Novartis$47K
- Neurocrine Biosciences, Inc.$40K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$31K
- plus $12K from 1 others
What the payments were for
- Consulting fees$22,8588%
- Speaking & faculty fees$161,39660%
- Travel & lodging$34,42313%
- Food & beverage$51,77719%
- Education$520%
- Gifts$5060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$205,755
- ARISTADA$98,688
- Austedo XR$39,783
- CAPLYTA$36,795
- REXULTI$27,549
- BRINTELLIX$26,252
- ARISTADA INITIO$24,335
- ABILIFY MAINTENA$21,302
- AUSTEDO$20,387
- Lucemyra/Lofexidine$9,329
- INGREZZA$8,447
- ESCITALOPRAM$5,248
- LATUDA$4,513
- UZEDY$1,879
- Auvelity$1,195
- VRAYLAR$1,010
- NEUROSTAR TMS THERAPY$600
- INVEGA SUSTENNA$512
- ZIMHI$506
- VNS Therapy Symmetry Model 8103 Generator$490
How this compares
$271,013 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 25 | $93,383 |
| AristadaAripiprazole Lauroxil | 29 | $84,414 |
| VraylarCariprazine Hcl | 35 | $51,217 |
| AuvelityDextromethorphan Hbr/Bupropion | 30 | $43,633 |
| CaplytaLumateperone Tosylate | 20 | $32,645 |
| RexultiBrexpiprazole | 15 | $29,739 |
| BelsomraSuvorexant | 12 | $8,558 |
| Aripiprazole | 66 | $8,383 |
| TrintellixVortioxetine Hydrobromide | 11 | $7,007 |
| Rivastigmine | 21 | $5,858 |
| Asenapine Maleate | 15 | $5,594 |
| Olanzapine | 85 | $4,868 |
| Clozapine | 33 | $4,758 |
| Quetiapine Fumarate | 231 | $3,518 |
| Bupropion XlBupropion Hcl | 107 | $2,845 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $3,707 | $93,38325 claims |
| Alkermes, Inc.Aristada | $78,280 | $84,41429 claims |
| AbbVieVraylar | $5,307 | $51,21735 claims |
| Axsome Therapeutics, Inc.Auvelity | $1,901 | $43,63330 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $40,167 | $32,64520 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $3,311 | $29,73915 claims |
| MerckBelsomra | $160 | $8,55812 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $798 | $7,00711 claims |
| Lilly USA, LLCOlanzapine | $64 | $4,86885 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Costa Mesa
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.